1	Third vaccine doses could have indirectly averted >100,000 deaths in the USA by reducing
2	transmission of the SARS-CoV-2 Delta variant
3	Billy J. Gardner*, A. Marm Kilpatrick*
4	
5	Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, Santa
6	Cruz, California, 95064 USA
7	*To whom correspondence should be addressed: wjgytc14@gmail.com; akilpatr@ucsc.edu
8	A. Marm Kilpatrick
9	130 McAllister Way
10	EE Biology/CBB
11	University of California
12	Santa Cruz, CA 95060
13	Preprint Server: medRxiv: https://www.medrxiv.org/content/10.1101/2021.10.25.21265500
14	Classification Biological Sciences: Applied Biological Sciences
15	Keywords COVID-19; vaccine effectiveness, surrogates of protection, vaccination; waning
16	immunity; herd immunity, modeling

Abstract

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Vaccination programs often focus on direct protection of individuals against disease and discount reductions in transmission, which can result in preventable disease and death. Initial clinical trials for most COVID-19 vaccines only measured direct protection, and dosing and vaccine selection decisions have, so far, ignored effects on transmission. Here we provide an empirical framework for incorporating indirect effects of COVID-19 vaccination on transmission in a continuous dynamic immune landscape. For the first time, we quantified relationships between neutralizing antibody titers and vaccine effectiveness for both susceptibility (VEs) and infectiousness (VE_I) and quantified changes in VE with waning and boosting of immunity. We used these relationships to quantify the impact that additional doses of mRNA vaccines (BNT162b2 and mRNA-1273) could have had in reducing transmission and deaths caused by the deadliest SARS-CoV-2 variant, Delta, in Autumn 2021. Neutralizing antibodies waned 8-fold in 2021 over the six months following initial vaccination with mRNA vaccines, which reduced VEs 33-38% (from 75-81% to 47-54%) and VE_I 62-65% (from 47-57% to 16-22%) against the Delta variant. Third doses increased neutralizing antibody titers 13-26-fold, which more than restored VE and reduced the relative risk of transmission 7-10-fold. Administering third doses by September 1, 2021 could have reduced the effective reproductive number R_t by 19%, stopped surges in transmission in many populations, and averted an estimated 111,491 deaths in the United States. Vaccination programs that incorporate effects on transmission in trial design, vaccination frequency, and vaccine choice are needed to address current and future public health challenges.

Significance

Vaccination programs for many diseases often focus primarily on people at risk of severe disease and sometimes discount indirect reductions in transmission. We developed a framework for estimating the effects of vaccination on transmission and used it to estimate the number of COVID-19 deaths that could have been averted by deploying third doses during the Delta variant surge to reduce transmission. We show that immunity against transmission had waned significantly in late 2021. However, widespread deployment of third doses could have restored protection, stopped surges of the Delta variant, and prevented more than 100,000 deaths in the United States. Vaccination programs should incorporate effects on transmission in initial trial design, vaccination frequency, and vaccine selection to address public health challenges.

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Vaccination is the most effective tool for reducing disease, hospitalizations, and deaths for many infectious diseases ^{1–5}. Core components of vaccination programs include how to allocate vaccine doses within and between individuals, when to recommend new doses and, when multiple vaccines are available, which vaccines to recommend. In making these decisions and developing new vaccines, public health agencies often focus on the direct impact of vaccines in reducing disease in vaccinated individuals ^{6,7}. For example, the United States Food and Drug Administration guidelines for randomized control trials for COVID-19 vaccines did not include any criteria regarding protection against infection or reductions in infectiousness 8, and, as a result, these weren't measured in the US trials for mRNA vaccines made by Pfizer-BioNTech and Moderna. Similarly, vaccines are often only recommended for subsets of the population at high risk disease severity 9, despite the fact that in many cases, such as pneumococcal disease, vaccines have been shown to reduce transmission ¹⁰. Many vaccines can have population-wide benefits by reducing transmission either by

Many vaccines can have population-wide benefits by reducing transmission either by reducing susceptibility or reducing infectiousness (i.e. transmission from breakthrough infections), or both, which indirectly protects additional individuals ¹¹. In these cases, vaccinating individuals who are not at risk of severe disease can reduce severe disease through reductions in transmission ¹². Deploying vaccines to reduce transmission can increase health equity by reducing infection in individuals that lack access to health care, including vaccination, which is a key global challenge ¹³. However, determining whether the benefits of deploying vaccines to reduce transmission is warranted requires estimating vaccine effectiveness (VE) for transmission and the potential number of deaths averted for a specific population, which, in turn, depends on the dynamic levels of population immunity for the pathogen in question.


The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 in 2021 illustrates the potential benefit of using vaccination to reduce transmission. The Delta variant caused a surge of deaths globally, even in populations with high initial two-dose vaccination coverage ¹⁴. This was due, in part, to the higher infectiousness and severity of this virus variant ^{15,16}, partial immune evasion ¹⁷, and, critically, waning vaccine immunity. Waning immunity was evident in both levels of neutralizing antibodies and studies of vaccine effectiveness, including for severe disease in older individuals ^{18,19}. To address the surge in COVID-19 in autumn 2021, third vaccine doses were offered to older ages and at risk individuals, but were not initially offered to healthy younger individuals because VE for severe disease in these age groups remained relatively high ²⁰. However, the potential impacts of offering third doses to all individuals to reduce transmission was not considered because of a lack of information on the benefits of indirect protection ²¹.

Here we estimate the potential impact of third doses of mRNA vaccines on population-level transmission of the Delta variant in late 2021 and the number of deaths that could have been averted. We first estimated how VEs and VE1 change over time due to waning and boosting of immunity. Previous work has demonstrated strong correlations between a surrogate measure of protection, neutralizing antibody titers, and VE for symptomatic and severe disease ^{22–27}, and one study used these relationships to examine the impacts of vaccination for averting disease and deaths²⁶. Here, we extend this approach by developing the first relationships, for any pathogen, between neutralizing antibody titers and VEs and VE1, which are required to estimate the impact of vaccination on transmission. We then quantified relationships between neutralizing antibody titers and time since vaccination, and following boosting with a third dose of mRNA vaccines. We integrated these two relationships to estimate the potential impacts of deploying additional

vaccine doses on the reproductive number of the virus, R_t , under multiple scenarios. Finally, we estimated the number of Delta infections and deaths that could have been averted in the United States in Autumn 2021 by deploying third doses to reduce transmission.

Results

We found very strong relationships between variant- and vaccine-neutralizing antibody titer ratios (NATR_{tot}) and VE using 23 estimates of VEs (susceptibility) and 14 estimates of VEI (infectiousness) across three variants and four vaccines (Figure 1A,B; Table S1). VEs was higher than VEI across the range of NATR_{tot} observed, but the slope of VEI was higher (VE increased more rapidly as NATR_{tot} values increased) (Figure 1; Table S1).



109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

Fig. 1. Vaccine Effectiveness (VE) plotted against variant- and vaccine-specific neutralizing antibody titer ratios (NATR_{tot}) for (A) susceptibility, VE_S, (B) infectiousness, VE_I, and (C) transmission VE_T. Each point (and 95% CI) represents a single empirical estimate of VE for a single vaccine (or infection) & virus variant. Points are jittered slightly along the xaxis to facilitate presentation. Black lines and ribbons in (A) and (B) show the fitted model and 95% CIs. The line and 95% CI ribbon in (C) is estimated from lines in (A) and (B): $VE_T = 1-(1-VE_S)*(1-VE_I)$; see Methods for details. In the eight months after vaccination, neutralizing antibody titers waned approximately 8fold for vaccine-derived immunity for both BNT162b2 and mRNA-1273 vaccines and 3-fold for infection derived immunity, with most waning occurring in the first 3-5 months (Figure 2A, B; Table S2). Rates of waning were faster for the BNT162b2 vaccine than the mRNA-1273 vaccine and infection-derived immunity (Figure 2B; Table S2). Initial neutralizing antibody titers were highest for vaccination with mRNA-1273, followed by BNT162b2, and lowest following infection (Figure 2A; Table S2). We used the relationships between neutralizing antibody titers and VE (Figure 1) and patterns of waning of antibody titers (Figure 2A, B) to estimate the waning of VEs and VEI over time (Figure 2C, D). As expected from levels of antibody titers, VE_S and VE_I were highest for two-dose vaccination with mRNA-1273, and BNT162b2 vaccines, and then infection-derived immunity (Figure 2C, D). The relatively fast waning rate of neutralizing antibodies for the BNT162b2 vaccine suggests that VE for this vaccine was initially much higher than infectionderived immunity, but the two were similar after 3-4 months (Figure 2C, D). VE for the mRNA-1273 vaccine remained higher than both the BNT162b2 vaccine and previous infection as protection waned (Figure 2C, D).

A third dose of the BNT162b2 vaccine boosted antibody titers 26-fold relative to levels after 8 months of waning, or 25.9/8.1 = 3.2-fold higher than one week after dose two 28 . A third dose of the mRNA-1273 vaccine boosted antibody titers 13-fold relative to 8-month waned levels, or 1.5-fold higher than shortly after the second dose. The fitted relationship between VEs and neutralizing antibody titer ratios (Figure 1) suggested that third doses of the mRNA vaccines would increase VEs 1.6-1.8-fold from waned values of 47-54% to boosted values of 85-86% and would boost VE_I 3-4-fold from 16-22% to 65-68% (Table S3; Figure 2C,D; compare blue and purple points in upper right of panels to lines of the same color below). Combined, boosting waned individuals with a third vaccine dose increased VE for transmission (VE_T = 1-(1-VE_S)*(1-VE_I)) from 55.4% to 95.4% for BNT162b2 and from 64.3% to 94.5% for mRNA-1273. In doing so, boosting reduced the risk of transmission (1-VE_T) by ~10-fold or 89.7% for BNT162b2 and ~7-fold or 84.5% for mRNA-1273 vaccinated individuals compared to waned immunity.




Figure 2. Waning of neutralizing antibody titers and VE for susceptibility (VE_S) and infectiousness (VE_I) over time and following boosting with a third dose. Lines show fitted models and ribbons show \pm 1 SE (Table S1). A) Neutralizing antibody titers relative to convalescent sera with wild-type (WT) virus, adjusted for the 2.2-fold lower neutralization titers with the Delta variant relative to wild-type virus. B) The same data as in panel A but rescaled relative to the initial peak value (i.e. all lines start at a value of 1) to show relative

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

rates of waning and levels of stabilization (Table S1). C) VE for susceptibility (VE_S) over time using the patterns of waning in Panel A and the relationships between antibody titers and VE for susceptibility (Figure 1A). D) VE for infectiousness (VE_I) over time using the patterns of waning in Panel A and the relationships between antibody titers and VE for infectiousness (Figure 1B). Points in the upper righthand corner of panels C and D, indicated by the black arrows, show the effect of third doses in boosting VE for the BNT162b2 and mRNA-1273 vaccines.

Next, we examined the impacts of third doses on population-level transmission in the United States via reductions in the reproductive rate of the pathogen, Rt. On September 1, 2021, the average time since vaccination for vaccinated individuals (53.2% of the population) was 4 months (118.3 days) (Figure S1) resulting in average antibody titers waning to less than 22% of peak values. If all doubly vaccinated individuals in the USA received a third dose of an mRNA vaccine that took effect on 1 September 2021 this would have reduced R_t by 18.4% (95% CI: 15.0% to 21.8%) from 1.17 to 0.96 (Figure 3D). This would have stopped the strong surge in cases, hospitalizations, and deaths that occurred over the next few months, assuming contact rates and other behaviors didn't change following boosting (see Methods for further details). Notably, using the same number of doses to doubly vaccinate unvaccinated individuals (assuming they were willing to be vaccinated) rather than boost previously vaccinated individuals would have been similarly effective in reducing transmission (Rt would decrease from 1.17 to 0.94 versus 1.17 to 0.96 for using doses for boosting vaccinated individuals) (Figure 3D, compare right end of red line to red point labeled " $R_0 = 3.2$, 79.8% vacc., no 3rd doses" on left side). We also explored several other scenarios with varying vaccination and infection rates and contact rates, which showed that the percent reduction in R_t was driven primarily by the

fraction of the population vaccinated, which determined the potential boosting fraction

(Supplemental Results Text, Figure S2).

174

175

177

178

179




Figure 3. United States population vaccination and infection history over time, population-level vaccine effectiveness against susceptibility (VE_S) and infectiousness (VE_I) over time, and the relationship between the pathogen effective reproductive number, R_t and third dose coverage, as of 1 September, 2021. A) Fraction of the US population that had received

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

their primary vaccination series but had not been infected (Frac. Vacc.), had been infected but not vaccinated (Frac. Inf.), had been both vaccinated and infected (Frac. Hybrid), or had received their third-dose booster (Frac. Boost). B) and C) Lines ± 1 SE show population-level VE against susceptibility (B) and infectiousness (C) over time for three subpopulations (vaccinated with their primary series, previously infected, and both vaccinated and previously infected [hybrid]) and the entire population in the US ("Total") which is a mixture of the five subpopulations, as shown in panel (A). Rectangles above panels (A-C) show which variant was dominant during the period (frequency $\geq 50\%$). D) Line ± 1 SE shows R_t plotted against the fraction of vaccinated individuals receiving third dose boosters for the United States with $R_0=3.2$, 53.2% vaccinated, and 67.4% previously infected as of September 1, 2021 (see Methods for additional details). The single red point shows the impact of using all third doses from the right end of the red line to doublyvaccinate unvaccinated individuals, which would bring the vaccination coverage from 53.2% to 79.8%. The dashed horizontal line shows the threshold reproductive number R_t 1, separating growing from shrinking epidemics. Between June 2021, when the Delta variant emerged, and January 2022, the Delta variant caused an estimated 273,801 deaths ¹⁴, with the average number of estimated daily cases sometimes exceeding 200,000 (Figure S3), and reported deaths sometimes exceeding 2,000/day (Figure 4). However, during this period the estimated R_t for the US population mostly fluctuated between 0.9 and 1.1 (Figure S3), suggesting that many thousands of deaths could have been prevented if R_t could have been reduced, even marginally. As we just illustrated, boosting the 53.2% of the population that had been vaccinated with a third dose by 1 September, 2021 would have reduced Rt by 18.4% (Figure 3D, red line). This would have reduced the number of Delta

deaths by 111,525 (95% CI: 103,819 to 116,641) (Figure 4E, blue shaded region) by averting 37,174,963 infections (95% CI: 34,606,246 – 38,880,500) (Figure 4A, orange shaded region). Boosting with third doses could have averted 629.5 (95% CI: 586.0 to 658.3) deaths per million vaccine doses administered due to effects on transmission alone.




Figure 4. Estimated daily infections (A-D) and reported or estimated deaths (E-H) with and without third dose boosting plotted against time in the United States when the Delta SARS-CoV-2 variant was dominant. Black lines in the left panels show the estimated number of infections each day, calculated by deconvolution using the observed daily deaths (dark blue lines in right panels) and the delays between infection and death, and using and an infection fatality ratio (IFR) of 0.003 ²⁹. Deaths from the Delta variant were estimated using reported deaths and variant fractions based on sequencing data (see Methods). Red lines in left panels show the estimated number of infections with third dose boosting, and light blue lines show the number of deaths resulting from these infections with the timing estimated

by reconvolution given the same distributions. The shaded regions show the averted infections (orange) and deaths (blue) if all eligible vaccinees received third doses that took full effect on Sept. 1, Oct. 1, Nov. 1, or Dec. 1 as indicated on the panel title with the reduction in R_t for these dates shown in Figure S2.

Boosting populations after Sept. 1 would have resulted in greater reductions in R_t as immunity in the vaccinated group continued to wane but would avert fewer deaths caused by the Delta variant. Boosting on October 1, November 1, or December 1 would have reduced R_t by 29.7%, 31.2%, and 30.0%, respectively (Figure S2), but would avert 73,574 (95% CI: 69,253 – 75,962), 36,424 (95% CI: 33,085 – 38,350) and 5,970 (95% CI: 5,039 – 6,617) Delta deaths (Figure 4; Table S5).

Discussion

The indirect effects of vaccination in reducing disease by reducing transmission (via reduced susceptibility or infectiousness) were rarely considered at any stage of COVID-19 vaccination programs, including initial trial design, initial vaccination, and subsequent boosting. We found that boosting population immunity with third vaccine doses could have substantially reduced transmission of the most deadly SARS-CoV-2 variant, Delta, stopped surges, and averted huge numbers of deaths in many populations, including more than 100,000 in the US. We estimated that 629 deaths could have been averted per million vaccine doses which is similar to or higher than the direct effects of COVID-19 vaccination in other studies (93 to 836 deaths per million doses administered ^{30–33}). However, many countries initially offered third doses only to protect at-risk individuals and only later offered third doses to the general population ²⁰. Likely as a result, third dose uptake by the general population in most countries was low. It may

have been higher if the third dose boosters were immediately and strongly recommended, or mandated for the whole population ³⁴.

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

The approach we developed here provides an empirical framework for estimating the effect of vaccination on transmission in a dynamic immune landscape. The key components are the temporal dynamics of a surrogate of protection neutralizing antibody titers and relationships between neutralizing antibody titers and the two components of transmission: susceptibility and infectiousness. Previous studies have shown that neutralizing antibody titers were strongly correlated with VE for symptomatic disease and severe disease ^{22–24,26,27}. Here, we significantly advanced this approach by showing that antibody titers were also strongly correlated with VEs and VE_I. This advance is critical for building accurate mathematical models of SARS-CoV-2 transmission as immunity wanes and is boosted with additional vaccine doses or infection. Previous models have assumed VE for transmission was the same as VE for symptomatic disease²⁶, which underestimates susceptibility (the relative risk of infection) and underestimates transmission (Figure S4). A similar empirical framework for estimating the effect of vaccination on transmission could be developed for other pathogens, such as influenza virus, but it would require a surrogate of protection³⁵ and multiple estimates of vaccine efficacy for susceptibility and infectiousness in population with different levels of immunity.

We found that VEs and VE_I declined rapidly in the first 3-5 months post-vaccination in BNT162b2 recipients and plateaued after ~6 months, with slower, waning in mRNA-1273 recipients, which may or may not be related to long lasting plasma cells ^{36,37}. These rates of waning suggest that vaccinating individuals multiple times per year would have substantially increased VE for transmission against the Delta variant, and would likely increase VE for transmission for the currently circulating SARS-CoV-2 variants as well. Given the summer

surges of COVID-19 hospitalizations that now appear to be a repeatable phenomenon, recommending two vaccine doses per year for COVID-19, especially in sensitive settings such as skilled nursing facilities, could provide substantial benefits.

We found third vaccine doses could have reduced Delta deaths dramatically, but the impact depended on the timing when doses were administered. Rolling out third doses by September 1 would have averted an additional 37,951 Delta deaths in the US compared to waiting until October 1, which emphasizes the timeliness of vaccinations. Two related factors made a September 1 rollout especially impactful. First, infections were near their peak in September. Second, Rt was below 1.03 from September 1 until late November when the Omicron variant began to invade. The potential reduction in Rt due to third doses (18.4%) was sufficient to reduce Rt well below 1 which would have driven Delta infections and deaths down rapidly (Figure 4). Administering third doses later would have averted fewer deaths caused by the Delta variant (but may have averted additional infections and deaths caused by the Omicron variant).

Our study has several limitations. First, our analyses use population averages for estimates of VE_S and VE_I and ignore age-specific variation among individuals, as well as other factors. Age-specific patterns of contact, disease severity, and immunity can play a key role in shaping epidemics ³⁸. We also assumed well-mixed populations in calculating reductions in the reproductive number R_t. A targeted vaccination approach would be more effective than that outlined here if highly connected individuals could be targeted for third doses ³⁹. Third, our calculations for the reductions in R_t with third doses were based on neutralizing antibody titers one month after the administration of a third dose. Neutralizing antibody titers also decay following third doses, but the decay rate is much slower than after second doses ⁴⁰, suggesting that substantial reductions in R_t from third doses would persist for many months, as we assumed

here. Fourth, our analyses were focused on population characteristics in the US in late 2021 and vaccine effectiveness against the Delta variant because data were available for quantifying immunity in populations at this time. The current impact of vaccine doses on transmission of SARS-CoV-2 is more difficult to quantify with currently available data, due to a more complex immune landscape, with most people having been infected several times with multiple virus variants and vaccinated with multiple vaccine types, and the variant composition of SARS-CoV-2 viruses is sometimes diverse and changes frequently. Determining the current benefit of vaccination for reducing transmission would require estimates of the distribution of neutralizing antibody titers against currently circulating viruses in target populations, and measuring increases in antibody titers following vaccination. Finally, quantifying the impact of vaccination in reducing deaths due to reduced transmission does not take into account additional benefits of reduced infections including reduced absenteeism from work and school and reduced cases of long COVID. The total benefits of reduced transmission may outweigh the costs of administering additional vaccine doses in many populations.

In summary, we showed that the indirect benefits of vaccination in reducing transmission can lead to a huge number of deaths averted. In addition, reductions in transmission increase health equity by reducing infection in individuals that lack access to vaccination. Quantifying vaccine impacts on transmission should be an integral part of developing new vaccines, and estimates of reductions in transmission should be used for planning vaccination strategies, including vaccine selection, targeting, and vaccination schedules.

Methods

Relative neutralizing antibody titers by variant, vaccine dose and with waning

We collected data on neutralizing antibody titers from the literature and estimated the total neutralizing antibody titer ratio (NATRtot) for each vaccine, virus variant, and immune status ²⁴. NATR_{tot} is the ratio of neutralizing antibody titer for a given vaccine, variant and immune status, relative to the neutralizing antibody titer of convalescent sera after infection with the original wild-type virus ^{24,27}. For example, two weeks after a second dose of the BNT162b2 vaccine NATR_{tot} for the Delta variant is 1.08, because vaccination with BNT162b2 results in neutralizing antibody titers 2.37-fold higher than infection ^{24,27}, and neutralizing antibody titers against the Delta variant are 2.20-fold lower than against wild-type virus; $2.37*(1/2.2) = 1.08^{24}$. We also collected data from studies measuring neutralizing antibody titers over time in sets of individuals following infection or vaccination to quantify waning of neutralizing antibody titers, as well as increases in antibody titers following boosting with third doses^{28,41,42}. We then fit models to the decay in antibody titers over time following vaccination with two mRNA vaccines (BNT162b2 and mRNA-1273), and infection (Table S1). We assumed antibody titers from hybrid immunity (infection followed by vaccination) waned at the same rate as following BNT 162b2 vaccination based on a study that measured both ⁴².

VE for susceptibility and infectiousness

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

We collected VE estimates for susceptibility and infectiousness for SARS-CoV-2 from the literature, including a systematic living review ⁴³, and categorized each study by vaccine, time since vaccination, and variant type (wild-type/D614G, Alpha, Delta). We excluded estimates where the virus variant could not be determined. For estimates of VEs, we only included studies where the endpoint was "all infections" (often measured using frequent testing or serology) and excluded studies where the endpoint was "any infection" because "any

infection" studies do not capture all infections and include an unknown fraction of asymptomatic infections. Studies of VE_I, or transmission given infection, usually compared secondary attack rates in households by vaccination status of the index case.

To fit a relationship between VE and NATR, we needed estimates of the number of infections in the vaccine and control groups. However, most studies did not report the number of infections; however, all reported a VE and 95% CI. We estimated the effective number of infected individuals in the control group (I_c) and the effective number of infected individuals in the vaccine group (I_v) for each study by determining the number of each needed to match the mean and 95% CI given in a study. We held the effective number of individuals in the control group (N_c) and vaccine group (N_v) constant at 1,000,000 because the 95% CI was invariant to variation in these values for observed incidence values. We used a maximum value of 1000 infections in the control group (I_c) to reduce the undue leverage of some very large studies ⁴⁴.

Relationships between VE and neutralizing antibody titers by vaccine and variant

We modeled the relationship between VE and total neutralizing antibody titer ratios (NATR_{tot}) using ²⁴:

349
$$VE = 1 - \frac{1}{1 + e^{-(c_0 + c_1 \log_2(NATR_{tot}))}}$$
 (1)

We estimated the coefficients c_0 and c_1 separately for the two endpoints, susceptibility and infectiousness, by maximizing the likelihood of observing the data underlying the VE estimates: the number of infections in the control group, I_c , and vaccine group, I_v , for each study. The likelihood was the product of two binomial distributions with N_c and N_v individuals:

$$L(N_c, I_c, N_v, I_v | NATR_{tot}, b_s, c_0, c_1) = Bi(N_c, I_c, b_s) * Bi(N_v, I_v, b_s * VE)$$
 (2)

Here b_s is the baseline risk for the study period, which is the fraction of control individuals infected during the study. We maximized the likelihood across all studies which was the product of the likelihoods of the individual studies. We used the fitted relationships for the two endpoints, susceptibility and infectiousness, between VE and neutralizing antibody titer ratios, NATR_{tot} (eq 1) to estimate VE for populations based on the estimated NATR_{tot} given the timing of vaccination and infection and estimated rates of waning as described above. Finally we calculated the VE for transmission, VE_T = 1-(1-VE_S)*(1-VE_I). We calculated 95% CIs for VE_T using independent bootstrap samples from the VE_S and VE_I estimates and 95% CIs.

Vaccine effectiveness over time

We estimated VEs and VE_I in the US for each day from January 1, 2021 to December 13, 2021 for three subpopulations: previously infected and unvaccinated, twice vaccinated and no previous infection, and twice vaccinated and previously infected (hybrid immunity), the timing of prior infections and vaccinations (Figure S1), and the relationships between neutralizing antibody titers and VE_I and VE_I. We estimated the timing of infections using reported deaths ⁴⁸ and deconvolution, using the distributions for the delays between infection and death (i.e. infection to shedding, shedding to symptom onset, symptom onset to hospitalization, and hospitalization to death) (Table S6) using the deconvolve package in R ⁴⁵. For each day, we estimated VEs and VE_I in each subpopulation against each circulating variant based on the timing of infections and vaccinations, accounting for the waning that occurred in each subpopulation on that date using the fitted model for the relationship between neutralizing antibodies and time since infection and vaccination. We used sequencing data from GISAID ^{29,46} (offset by 9 days to account for the average delay between infection and reporting date) in the

US to get a variant-averaged estimate of VEs and VEI in each subpopulation for each day using a weighted mean where weights were the observed variant frequency each day. We then estimated a population-wide VE for each day using estimates for the fraction of the population in five subpopulations: fully susceptible, third-dose boosted, and the three subpopulations described above.

The impact of third doses on the reproductive number, R_t

We used patterns of waning and boosting of neutralizing antibody titers to estimate the impact of providing additional doses of mRNA vaccines to increasing fractions of vaccinated individuals in the USA and other populations on the reproductive number, R_t , of the Delta variant of SARS-CoV-2, at four time points in autumn 2021; Sept 1, Oct 1, Nov 1, and Dec 1 (Table S4). R_t is the average number of secondary cases that each case infects and is equal to the basic reproductive number for a pathogen in a fully susceptible population, R_0 , multiplied by the fraction of the population that is susceptible (i.e. not immune from vaccination or previous infection).

We examined the effect of boosting vaccinated individuals with a third dose on R_t by considering five scenarios which were combinations of vaccination, previous infection and contact rates that span the range of circumstances in many countries in late 2021. The five scenarios (with fraction vaccinated and previously infected shown for 1 September 2021) and rationale were (Table S4):

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

1) US/D (United States with distancing): $R_0 = 3.2, 53.2.\%$ vaccinated, 67.4% previously infected: approximated fraction of US population previously infected with contact rates similar to summer-fall 2021 2) CA/D (California, USA, with distancing): $R_0 = 3.2, 58.7\%$ vaccinated, 59.8% previously infected: approximated some populations with higher vaccination and lower fraction infected than scenario (1) (e.g. California) 3) NZ/ND (New Zealand, no distancing): R₀ = 7.0, 24.3% vaccinated, 0.2% previously infected: approximated countries with high vaccination rates that effectively suppressed transmission and had reduced contact rates when cases were detected (e.g. New Zealand, Australia, Hong Kong, etc.) 4) US/ND (United States, no distancing): $R_0 = 7.0, 53.2\%$ vaccinated, 67.4% previously infected: a scenario to compare to scenario (1) to determine if boosting could limit transmission if behavior returned to pre-pandemic levels 5) US/ND-100 (United States, no distancing): R0 = 7.0, 100% vaccinated, 67.4% previously infected: a hypothetical optimistic scenario to compare to scenario (1) to determine if vaccination with or without boosting could limit transmission if behavior returned to prepandemic levels We estimated the fraction of the population that was susceptible using data on the fraction of the population that had been vaccinated or infected or both. We first split each population into three groups based on vaccination status: fraction unvaccinated, f_U, fraction vaccinated, f_V, with two doses of either BNT162b2 or mRNA-1273, and fraction boosted with a third dose of the same vaccine used for the primary series, f_B (f_U+f_V+f_B=1). We calculated the fraction of people in the USA receiving BNT162b2 and mRNA-1273 from vaccination records ⁴⁷. We estimated the

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

timing of infections using deconvolution of deaths as described above and calculated the number of infections by dividing deaths by an estimate of the infection fatality ratio (IFR) across of 2020-21 of 0.003 ²⁹; the results were not sensitive to moderate variation in this estimate. We also examined estimating infections using cases and an infection/case ratio of 4.0 48 which produced a lower estimate of total infections, and the reduction in R_t with third dose boosting and deaths averted were very similar to the death-deconvolution and IFR method. We estimated the fraction of unvaccinated or vaccinated individuals that had been previously infected using the ratios of cases in these two groups over time in the USA 49 (Figure S5). We used vaccination and infection data to calculate the fraction of people previously infected among unvaccinated, fpu, and vaccinated, f_{PV} individuals (Table S4). We used rates of waning of antibody titers and data on the timing of vaccination and infection from the USA and New Zealand ⁴⁷ for US and New Zealand scenarios, respectively, to estimate the distribution of NATR_{tot} in populations for the four time points in autumn 2021. We used the distributions of NATR_{tot} to estimate the relative susceptibility, 1-VEs, (Figure 1A) and relative infectiousness, 1-VE_I, (Figure 1B) for the population in each of four groups: unvaccinated and previously infected (VE_{SP} and VE_{IP}), vaccinated twice and no previous infection (VEsv and VE_{IV}), vaccinated three times or boosted (VE_{SB} and VE_{IB}), and vaccinated and infected or hybrid immunity (VE_{SH} and VE_{IH}), all with appropriate adjustments for waning antibody titers (see below). We used these estimates of VE to calculate R_t for populations composed of different fractions of five groups: never infected unvaccinated (1-f_{PU})f_U, previously infected unvaccinated f_Pf_U, previously uninfected vaccinated with two doses (1-fpv)fv, previously infected and vaccinated with two doses fpvfv, and boosted with a third dose, regardless of previous infection, f_B:

443 $R_t = R_0 \left[(1 - f_{PU})f_U + f_{PU}f_U(1 - VE_{SP})(1 - VE_{IP}) + (1 - f_{PV})f_V(1 - VE_{SV})(1 - VE_{IV}) + (f_{PV}f_V)(1 - VE_{SH})(1 - VE_{$ 444 VE_{IH})+(f_B)(1-VE_{SB})(1-VE_{IB})] (3) 445 Note that in equation (3) the VE values for each population are integrated across the 446 distribution of NATRtot values for that group, and the distribution of NATRtot values in each 447 group reflects the timing of vaccination and infection on a daily timestep. 448 We used the scenario estimates of the fraction of population with different types of immunity 449 (with timing matched to vaccination and infection and waning as described above) for 450 susceptibility and infectiousness to estimate values of R_t under each scenario at the four time 451 points in autumn 2021 (Sept. 1, Oct. 1, Nov. 1, and Dec. 1; Table S4). We calculated 95% CIs for predicted values of R_t that incorporated uncertainty in the relationship between time since 452 453 vaccination or infection and NATR_{istatus}, uncertainty in the relationships between neutralizing 454 antibody titers and VEs and VEI, as well as uncertainty in NATR_{vac} and NATR_{var} (Figures 1 and 455 S2). 456 457 The impact of third doses on infections and deaths caused by the Delta variant 458 We estimated the timing of the infections that gave rise to observed deaths and total 459 infections in the United States in autumn 2021 using deconvolution as described above. We used SARS-CoV-2 sequencing data ^{29,46} to estimate the daily fraction of all infections that were 460 461 caused by the Delta variant. We estimated the reduction in Delta infections if third-dose boosters 462 were given to all fully vaccinated individuals at four time points in autumn 2021. We assumed 463 the additional doses would take full effect simultaneously on Sept. 1, Oct. 1, Nov. 1, or Dec. 1.

We estimated the number of Delta infections that would have occurred if third doses had been

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

deployed by multiplying the number of estimated infections on each day by the reduction in the daily R_t due to third doses (e.g. 0.812 if R_t was reduced by 18.8%), raised to the power of the number of generations of infections (generation time 3.8d ⁵⁰) since Sept 1 (or Oct. 1, Nov. 1 or Dec. 1). The calculated reduction in R_t was the difference between the number of actual thirddoses given, and the number of doses deployed in the scenario. We estimated the number of deaths that would have been averted in each scenario by re-convoluting the reduced infections, multiplied by the IFR, using the delays described previously. We used uncertainty associated with our R_t estimates to calculate 95% CIs in the number of deaths averted. **Author Contributors** BJG and AMK conceived the study, performed the analyses and wrote the paper. **Declaration of competing interests** All authors declare no competing interests. **Data sharing** All data used in the paper are contained in the supplemental material. R Code and data files to replicate the figures and analyses of this paper are available: https://github.com/marmkilpatrick/Vaccine-boosters Upon publication, R Code will be uploaded to Zenodo and data files will be archived with Dryad. Acknowledgements **Funding**

- We received funding from the National Science Foundation (DEB- 1911853, 1115895, and
- 487 1717498) and the California Department of Health.
- 489 **References**

- 490 1 Allen A. Vaccine—the controversial story of medicine's greatest lifesaver. New York, NY:
- 491 W.W. Norton & Co., 2007.
- 492 2 Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology
- 493 2015; **479–480**: 379–92.
- 494 3 Greenwood B. The contribution of vaccination to global health: past, present and future. *Phil*
- 495 *Trans R Soc B* 2014; **369**: 20130433.
- 496 4 Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable diseases, immunizations, and
- 497 MMWR--1961-2011. *MMWR Suppl* 2011; **60**: 49–57.
- 498 5 Roush SW. Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable
- 499 Diseases in the United States. *JAMA* 2007; **298**: 2155.
- 6 Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. Stat Methods Med Res 2004;
- **13**: 89–114.
- 502 7 Li X, Mukandavire C, Cucunubá ZM, et al. Estimating the health impact of vaccination
- against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a
- modelling study. *The Lancet* 2021; **397**: 398–408.
- 8 COVID-19: Developing Drugs and Biological Products for Treatment or Prevention. 2023.
- 506 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-
- developing-drugs-and-biological-products-treatment-or-prevention.
- 508 9 CDC. Child and Adolescent Immunization Schedule by Age. 2023.
- 509 https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
- 510 10CDC. Direct and indirect effects of routine vaccination of children with 7-valent
- 511 pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United
- States, 1998-2003. 2005. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436a1.htm.
- 513 11 Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. 1985.
- 514 12Medlock J, Galvani AP. Optimizing Influenza Vaccine Distribution. *Science* 2009; **325**:
- 515 1705–8.
- 516 13 Marmot M. Achieving health equity: from root causes to fair outcomes. *The Lancet* 2007;
- **370**: 1153–63.

- 518 14 Walker J, Grubaugh ND, Gonsalves G, Pitzer V, Rizvi Z. One Million and Counting:
- Estimates of Deaths in the United States from Ancestral SARS-CoV-2 and Variants. *medRxiv*
- 520 2022; : 2022.05.31.22275835.
- 521 15 Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global
- spread of SARS-CoV-2 variants of concern as at June 2021. Eurosurveillance 2021; 26.
- 523 DOI:10.2807/1560-7917.ES.2021.26.24.2100509.
- 524 16Elliott P, Haw D, Wang H, et al. Exponential growth, high prevalence of SARS-CoV-2, and
- vaccine effectiveness associated with the Delta variant. *Science* 2021; **374**: eabl9551.
- 526 17 Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to
- 527 antibody neutralization. *Nature* 2021; **596**: 276–80.
- 528 18Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta (B.1.617.2) and
- other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in
- health care workers, Israel. Eurosurveillance 2021; 26. DOI:10.2807/1560-
- 531 7917.ES.2021.26.26.2100557.
- 532 19Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies
- against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021; published online Jan
- 534 25. DOI:10.1101/2021.01.25.427948.
- 535 20Bar-On YM, Goldberg Y, Mandel M, et al. Protection Across Age Groups of BNT162b2
- Vaccine Booster against Covid-19. *medRxiv* 2021; published online Oct 7.
- 537 DOI:10.1101/2021.10.07.21264626.
- 538 21 Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune
- responses. *The Lancet* 2021; **398**: 1377–80.
- 540 22 Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection
- against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet*
- 542 *Microbe* 2022; **3**: e52–61.
- 543 23 Cromer D, Steain M, Reynaldi A, et al. Predicting vaccine effectiveness against severe
- 544 COVID-19 over time and against variants: a meta-analysis. *Nat Commun* 2023; **14**: 1633.
- 545 24 Gardner BJ, Kilpatrick AM. Predicting Vaccine Effectiveness for Hospitalization and
- 546 Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers.
- 547 *Viruses* 2024; **16**. DOI:10.3390/v16030479.
- 548 25 Hogan AB, Doohan P, Wu SL, et al. Estimating long-term vaccine effectiveness against
- SARS-CoV-2 variants: a model-based approach. *Nat Commun* 2023; **14**: 4325.
- 550 26Hogan AB, Wu SL, Toor J, et al. Long-term vaccination strategies to mitigate the impact of
- SARS-CoV-2 transmission: A modelling study. *PLoS Med* 2023; **20**: e1004195.

- 552 27 Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of
- immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**: 1205–11.
- 28 Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 Neutralization with BNT162b2
- 555 Vaccine Dose 3. *N Engl J Med* 2021; **385**: 1627–9.
- 556 29 Kilpatrick AM. Ecological and Evolutionary Insights About Emerging Infectious Diseases
- from the COVID-19 Pandemic. *Annu Rev Ecol Evol Syst* 2023; **54**: 171–93.
- 30 Kayano T, Sasanami M, Kobayashi T, et al. Number of averted COVID-19 cases and deaths
- attributable to reduced risk in vaccinated individuals in Japan. The Lancet Regional Health -
- 560 Western Pacific 2022; **28**: 100571.
- 31 Haas EJ, McLaughlin JM, Khan F, et al. Infections, hospitalisations, and deaths averted via a
- nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19
- vaccine in Israel: a retrospective surveillance study. *The Lancet Infectious Diseases* 2022; **22**:
- 564 357–66.
- 32 Santos CVBD, Noronha TGD, Werneck GL, Struchiner CJ, Villela DAM. Estimated COVID-
- 19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a
- retrospective observational study. *The Lancet Regional Health Americas* 2023; **17**: 100418.
- 33Mendes D, Chapman R, Gal P, et al. Public health impact of booster vaccination against
- 569 COVID-19 in the UK during Delta variant dominance in autumn 2021. *Journal of Medical*
- 570 Economics 2022; **25**: 1039–50.
- 34Mello MM, Opel DJ, Benjamin RM, et al. Effectiveness of vaccination mandates in
- improving uptake of COVID-19 vaccines in the USA. *The Lancet* 2022; **400**: 535–8.
- 573 35 Ward BJ, Pillet S, Charland N, Trepanier S, Couillard J, Landry N. The establishment of
- surrogates and correlates of protection: Useful tools for the licensure of effective influenza
- vaccines? *Human Vaccines & Immunotherapeutics* 2018; **14**: 647–56.
- 36Nguyen DC, Hentenaar IT, Morrison-Porter A, et al. SARS-CoV-2-specific plasma cells are
- 577 not durably established in the bone marrow long-lived compartment after mRNA vaccination.
- 578 *Nat Med* 2024; published online Sept 27. DOI:10.1038/s41591-024-03278-y.
- 37 Schulz AR, Fiebig L, Hirseland H, et al. SARS-CoV-2 specific plasma cells acquire long-
- lived phenotypes in human bone marrow. *eBioMedicine* 2023; **95**: 104735.
- 38 Yuan H-Y, Baguelin M, Kwok KO, Arinaminpathy N, Van Leeuwen E, Riley S. The impact
- of stratified immunity on the transmission dynamics of influenza. *Epidemics* 2017; **20**: 84–93.
- 39Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world
- network to model localized COVID-19 control strategies. *Nat Med* 2020; **26**: 1616–22.

585 40Gilboa M, Regev-Yochay G, Mandelboim M, et al. Durability of Immune Response After

586 COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. *JAMA*

- 587 *Netw Open* 2022; **5**: e2231778.
- 588 41 Chu L, Vrbicky K, Montefiori D, et al. Immune response to SARS-CoV-2 after a booster of
- 589 mRNA-1273: an open-label phase 2 trial. *Nat Med* 2022; **28**: 1042–9.
- 590 42 Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune
- memory to SARS-CoV-2 and variants of concern. *Science* 2021; **374**: abm0829.
- 592 43 Higdon MM, Wahl B, Jones CB, et al. A Systematic Review of Coronavirus Disease 2019
- Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus
- 2 Infection and Disease. *Open Forum Infectious Diseases* 2022; **9**: ofac138.
- 595 44Lewnard JA, Patel MM, Jewell NP, et al. Theoretical Framework for Retrospective Studies of
- the Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021; **32**: 508–17.
- 597 45Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission
- dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in
- California and Washington, United States: a prospective cohort study. 2020; published online
- 600 April 16. DOI:10.1101/2020.04.12.20062943.
- 46Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data from vision to
- 602 reality. Eurosurveillance 2017; **22**. DOI:10.2807/1560-7917.ES.2017.22.13.30494.
- 603 47 Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Our World
- 604 in Data. 2020.

- 48CDC. Estimated COVID-19 Burden. 2021. https://www.cdc.gov/coronavirus/2019-
- 606 ncov/cases-updates/burden.html.
- 49COVID Data Tracker. CDC. 2021. https://covid.cdc.gov/covid-data-tracker/.
- 50Park SW, Sun K, Abbott S, et al. Inferring the differences in incubation-period and
- 609 generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2.
- *Proceedings of the National Academy of Sciences* 2023; **120**: e2221887120.